TERMINAL AUDIT: THERANOS
SUBJECT: Series C ($30M Ask) | Pre-IPO / Late Stage
SECTOR: Healthcare & Bio
TERMINAL TRAJECTORY: Regulatory Shutdown / Complete Capital Loss
ENGINE: RUNE Protocol™ / Maximus v1.3.5
DATE EXECUTED: February 21, 2026
The Dual-Score Audit
PRESENTATION SCORE
42/100
CLARITY SCORE™
0/100
DELTA
-42
Severe Narrative Masking
JUDGE PROTOCOL OVERRIDE: Integrity Violation. The model projects a $1.5Bn "existing deals" pipeline for a 50-person entity lacking primary regulatory clearances. Clinical patient data is simulated.
RISK PATTERN: High-Conviction Fraud Exposure
REGULATORY EXPOSURE: 100%
Strategic Summary
Theranos is raising a $30M pre-IPO round on the back of unverified "gold standard" blood testing claims and a mathematically irreconcilable $1.5 billion revenue pipeline.
This deck exhibits severe Narrative Masking. It leverages cap-table signaling (prominent venture veterans and pharma partnerships) to obscure the absence of peer-reviewed, empirically validated clinical data. The gap between the stated narrative and the underlying business physics guarantees capital destruction.
RUNE Extraction: Business Physics (PHYS)
IMPOSSIBLE PIPELINE VELOCITY
The Claim:
$120M–$300M in recognized revenue within 18 months, supported by a $1.5Bn "existing deals" pipeline.
The Physics Failure:
The entity has 50 employees, zero mainstream FDA clearances, and unproven manufacturing scale. The revenue-to-headcount velocity violates all baseline medical device scalability math.
The Audit Gap:
RUNE flags a high probability that these $1.5Bn in "deals" are non-binding Memorandums of Understanding (MOUs) masquerading as committed purchase orders.
UNVERIFIED DEVICE PHYSICS
The Claim:
5–10μL sample size with <30m multiplex completion and 5–7% Coefficient of Variation (CV).
The Physics Failure:
Operating a micro-fluidic chemiluminescence platform at this volume without independent third-party validation is a structural physics violation.
The Audit Gap:
The Clarity Framework™ requires raw clinical trial data and independent lab verification of the 5-7% CV. Neither exists in the provided documentation.
UNIT ECONOMIC MASKING: SOFTWARE MARGINS ON HARDWARE
The Claim:
70% gross margins driven by a theoretical $7,500 "Information Fee" per patient.
The Physics Failure:
The company is projecting SaaS margins on physical cartridges, readers, and clinical services without demonstrating supply chain maturity or fully burdened COGS.
RUNE Extraction: Compliance (COMP)
ILLUSTRATIVE DATA PRESENTED AS EMPIRICAL
The Violation:
Slides 10-13 display clinical treatment curves that are statistically flawless, lack error bars, and visually mimic simulated marketing models.
The Audit Gap:
Presenting illustrative models as empirical patient data constitutes a severe regulatory compliance failure.
TOP-DOWN TAM ILLUSION
The Violation:
The narrative assumes a massive capture of the $39B Phase IV clinical market by applying a flat $50M per trial value. Zero bottom-up build is provided to justify this capture rate or pipeline conversion metric.
Algorithmic Score Breakdown
Raw Presentation metrics extracted by Maximus v1.3.5:
| Problem | 16/20 |
| Market | 8/20 |
| Ask | 6/20 |
| Solution | 6/20 |
| Model | 6/20 |
| Base Presentation Score | 42/100 |
The JUDGE Penalty Execution
Alpha Premium Applied: +0
Substance Penalty: -20
Severe Documentation Gap: Material reads as marketing collateral with zero verifiable diligence data.
Deterministic Kill Shot Penalty: Integrity Violation
Triggers an immediate collapse of the Clarity Score to absolute 0.
Directives for the Investment Committee
The JUDGE protocol mandates an immediate HOLD on all capital deployment. Do not proceed without executing the following Defensible Audit Log™ requirements:
HALT DILIGENCE
Demand all FDA correspondence and the complete regulatory strategy be provided directly to external legal counsel.
AUDIT THE PIPELINE
Demand binding MSAs. Exclude all non-binding MOUs from the $1.5Bn pipeline calculation.
MANDATE THIRD-PARTY VALIDATION
Require an independent, accredited laboratory to validate the 5-7% Coefficient of Variation claim on the proprietary hardware.
Confidence without integrity is a failure mode.
The RUNE Protocol™ detects the failure at compile-time.
Do not let bad business physics kill your raise. Or your fund.
For Founders
Do not let bad business physics kill your raise.
Stress-test your deck through the Crucible to find your compile-time errors before an Investment Committee does.
Audit Your DeckFor Capital Allocators
Scale diligence bandwidth without degrading alpha.
Standardize your deal flow and build a Defensible Audit Log™ for your LP base.
Scale Your DiligenceAssessment generated using the askOdin AI Judgment Infrastructure™. Confidential & Proprietary Methodology of askOdin Pte. Ltd. © 2026. This is a deterministic audit, not investment advice.